Expertise in
1
conditions

Sarah P. Blagden

Oxford, ENG, GB 
Expertise in
1
conditions
Oxford, ENG, GB 

Overview

Sarah Blagden practices practicing medicine in Oxford, United Kingdom.

Ms. Blagden is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Ovarian Cancer, Transient Erythroblastopenia of Childhood, Ascites, and Aase Syndrome.

She is actively involved in clinical research, co-authoring 90 peer reviewed articles and participating in 7 clinical trials.

Gender

Female

Locations

Oxford, ENG, United Kingdom
Other Locations
Liverpool, ENG, United Kingdom
Level 1A City Tower, Piccadilly Plaza, Manchester, ENG M14BT, United Kingdom
United Kingdom
London, ENG, United Kingdom
Lancaster, ENG, United Kingdom
Sarah Blagden, MBChB, Is Foundation Year Two Doctor, West Bromwich, United Kingdom. Thomas Kingstone, MSc, Is PhD Student, Staffordshire, United Kingdom. Andrew Soundy, PhD, Is Lecturer In Physiotherapy, Edgbaston, Birmingham, United Kingdom. Rhonda Lee, MBBS, MPh, Is Holistic Physician, C/O Freshwinds, Prospect Hall, Selly Oak, Birmingham, United Kingdom. Sukhdev Singh, MD, FRCP, Is Consultant Gastroenterologist, Rectory Road, Sutton Coldfield, West Midlands, United Kingdom. Lesley Roberts, PhD, Is Professor Of Medical Education And Pro Dean Education, Coventry, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Enrollment Status: Terminated
Publish Date: October 21, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment
A Phase Ib/II Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Two-part, Phase I Open Label, Dose Escalation and Expansion Study to Assess Safety, Pharmacokinetics and Clinical Activity of NUC-3373, a Nucleotide Analogue, in Participants With Advanced Solid Tumours
A Two-part, Phase I Open Label, Dose Escalation and Expansion Study to Assess Safety, Pharmacokinetics and Clinical Activity of NUC-3373, a Nucleotide Analogue, in Participants With Advanced Solid Tumours
Enrollment Status: Completed
Publish Date: February 14, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 22, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer
Enrollment Status: Completed
Publish Date: June 18, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid Malignancies
A Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid Malignancies
Enrollment Status: Terminated
Publish Date: June 11, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 6 Less Clinical Trials

90 Total Publications

Beyond data and technology: the need for new thinking to enable the era of precision prevention.
Beyond data and technology: the need for new thinking to enable the era of precision prevention.
Journal: BMC medicine
Published: March 09, 2026

Frequently Asked Questions about Sarah P. Blagden

Is Sarah P. Blagden a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Sarah P. Blagden is classified as an Distinguished expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Sarah P. Blagden participate in research or clinical trials?

Yes. Sarah P. Blagden has published 90 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Sarah P. Blagden's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Blagden's expertise for a condition
ConditionClose
      View All 21 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile